MedX Health Corp. (“MedX”) (MDX – TSXV), announced today that President and CEO Scott Spearn has resigned for family reasons, effective immediately. Rob von der Porten, Chairman of the Board, has been named interim Executive Chair. Mr. Spearn will also be retiring from the Board at or prior to the next AGM. The Board will commence a search for suitable candidates to take on the CEO position.
“The Board thanks Scott for his service and leadership, but we understand his decision to step down,” said Mr. von der Porten. “During his tenure as President and CEO, MedX has completed the development of its SIAscopy™ on DermSecure™ Telemedicine platform, has entered into major distribution arrangements and has significantly strengthened its balance sheet. We wish him the very best. I am confident that under the direction of MedX’s executive leadership team, the Company will enjoy continued success in the future.”
Mr. Spearn noted, “It has been a privilege to have led MedX during an important period of transformation and growth. I am proud to have worked with my MedX colleagues who are so committed to the development of the SIAscopy™ technology and the DermSecure™ Telemedicine platform that represents such a significant development in the diagnosis process for early detection of melanoma.”
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, Brazil, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.